Ask questions across claims linked to experiments, exact results, limitations, and sources.Know what the science actually supports before you trust the answer.
Press Enter ↵ to search evidence
Explore by Goal
"The most beautiful experience we can have is the mysterious. It is the fundamental emotion that stands at the cradle of true art and true science."
- Albert Einstein
Quick Explanation
Copied
Summary (very short): Methylene blue (MB) has documented clinical uses (methemoglobinemia antidote, vasoplegic shock rescue, photodynamic/antimicrobial/analgesic topical uses) and investigational effects (low-dose neurometabolic/antidepressant signals). Major contraindications/risks when used as a systemic supplement include severe risk in G6PD deficiency (hemolysis), risk of serotonin syndrome with serotonergic drugs, dose-dependent hemolysis/methemoglobin formation at very high doses, and drug–drug interactions; safety depends entirely on dose, route (oral topical vs IV), and patient comorbidities — do not self-supplement systemically without medical supervision.
Key sources: CPIC G6PD guidance; comprehensive methemoglobinemia review; clinical reports of MB in pain, photodynamic therapy, and vasoplegia were used and are cited below.
Long Explanation
Effects and contraindications of methylene blue (MB) as a supplement — evidence visuals + citations
Visuals first (bottom of page includes concise explanation + critical caveats). All claims below are inline-cited to primary sources.
Concise evidence-backed takeaways (visual → text)
Clinically validated uses: MB is an established antidote for methemoglobinemia (IV 1–2 mg/kg), and is used as a rescue agent for vasoplegia in selected settings; topical MB is used in photodynamic/antimicrobial therapy and as an oral rinse for refractory oral mucositis with small case series showing benefit
Major contraindication — G6PD deficiency: Clinical pharmacogenetic guidance classifies methylene blue as a high‑risk drug for causing hemolytic anemia in individuals with G6PD deficiency and recommends avoidance; enzyme testing or genotype-informed decisions are required for uncertain cases
Serotonergic interactions: MB is a monoamine oxidase inhibitor at some doses and has caused serotonin syndrome when combined with SSRIs/SNRIs/MAOIs — several case reports and pharmacology reviews warn of serious interactions; avoid concurrent serotonergic agents or use under strict medical oversight
Dose and route matter: Topical and low-dose oral use (e.g., rinses, PDT) produce limited systemic exposure and lower systemic risk; IV dosing used for methemoglobinemia or vasoplegia produces higher systemic exposure and the known systemic risks (hemolysis in G6PD deficient, paradoxical methemoglobinemia at very high doses)
Known adverse effects & monitoring: At clinical IV doses, MB can cause dyspnea, chest pain, hemolysis, and paradoxically can worsen methemoglobinemia at very high doses (≥15 mg/kg reported); monitoring with CO-oximetry and hemolysis labs is routine in clinical settings
Evidence gaps and supplement context: There is weak-to-no robust evidence supporting routine chronic oral supplementation of MB for general health or longevity; older small trials (e.g., a small depression trial) suggested CNS effects at low doses but are insufficient to justify OTC supplementation without safety data, especially given known drug interactions and G6PD risk
Critical practical guidance (evidence-weighted)
Do not self-administer systemic (oral high-dose or IV) methylene blue as a supplement — serious, preventable harms exist and depend on genotype (G6PD), medicines, and dose .
If you take SSRIs/SNRIs/MAOIs, MB can precipitate serotonin syndrome — do not combine without physician oversight .
Topical/low-systemic uses (photodynamic therapy, oral rinse) have markedly different risk profiles than systemic IV dosing; topical MB for oral mucositis showed symptomatic benefit in small series but lacks large RCTs .
Limitations, blindspots, and what would change conclusions
Existing evidence is a mix of guidelines, narrative reviews, case reports/series, small trials, and mechanistic studies. Large randomized trials testing chronic oral MB supplementation for general health or cognitive effects are absent. The strongest, most actionable evidence concerns acute clinical uses and genetic contraindications (G6PD). New randomized safety data in diverse populations or demonstration of safe chronic dosing regimens with careful pharmacovigilance would change the balance toward or against supplement use.
Selected primary citations (used above)
Bottom line:
Methylene blue has important, evidence-backed clinical applications but also important and potentially severe contraindications (notably G6PD deficiency and serotonergic drug interactions). The evidence does not support unsupervised systemic supplementation; topical or clinician-directed low-dose uses (e.g., oral rinse, PDT) have lower systemic risk but still limited high-quality evidence for broad supplementation claims.
Preparing scripts to integrate CPIC G6PD allele frequencies with population medication lists to compute population-level contraindication prevalence for MB.
Get emailed when your analysis is done!
We'll email you the results when your analysis is finished.
Hypothesis Graveyard
MB is universally safe as an OTC supplement — falsified by consistent evidence of severe adverse events in G6PD deficiency and serotonergic interactions.
Low-dose MB has no pharmacologic systemic activity — contradicted by small CNS trials showing behavioral effects and documented pharmacologic interactions at surprisingly low doses.
Quick Explanation
Long Explanation
Top Data Sources
ExportMCP
Analysis Wizard
Hypothesis Graveyard
Potential Experiments
Discussion
Explore by Goal
Ask a Follow-Up
Key Insight
Keep Exploring
